Assessment for chronic kidney disease service in high-risk patients at community health clinics

Annals of Pharmacotherapy

Volumn 39, Issue 1, 2005, Pages 22-27

  Patel, Harita R ^a   Pruchnicki, Maria C ^b   Hall, Laura E ^b  

^a UNIVERSITY OF FLORIDA HEALTH JACKSONVILLE   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

Ambulatory care; Chronic kidney disease; National Kidney Foundation

Indexed keywords

HEMOGLOBIN; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; BIOLOGICAL MONITORING; BLOOD PRESSURE; CHRONIC KIDNEY DISEASE; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CREATININE CLEARANCE; DISEASE COURSE; GLOMERULUS FILTRATION; GLYCOSYLATION; HEALTH CENTER; HEALTH SERVICE; HEMOGLOBIN DETERMINATION; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MEDICAL ASSESSMENT; MEDICAL RECORD; PHARMACIST; PRIORITY JOURNAL; REVIEW; SCREENING TEST;

ADULT; AGED; AGED, 80 AND OVER; AMBULATORY CARE; AMBULATORY CARE FACILITIES; COMMUNITY PHARMACY SERVICES; DIABETES COMPLICATIONS; FEMALE; HUMANS; HYPERTENSION; INTERPROFESSIONAL RELATIONS; KIDNEY FAILURE, CHRONIC; MALE; MEDICAL INDIGENCY; MIDDLE AGED; OHIO; PHARMACOLOGY, CLINICAL; RISK FACTORS;

EID: 11144221313     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1E269     Document Type: Review

References (21)

1. US Renal Data System: USRDS 2003 annual data report: atlas of endstage renal disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2003.
2. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002;39(2 suppl 1):S24,S32-75.
3. Jones CA, McQuillan GM, Kusek JW, Eberhardt MS, Herman WH, Coresh J, et al. Serum creatinine levels in the US population: third National Health and Nutrition Examination Survey. Am J Kidney Dis 1998;32:992-9. Erratum 2000;35:178.
4. Manley HJ, McClaran ML, Overbay DK, Wright MA, Reid GM, Bender WL, et al. Factors associated with medication-related problems in ambulatory hemodialysis patients. Am J Kidney Dis 2003;41:386-93.
5. Kaplan B, Mason NA, Shimp LA, Ascione FJ. Chronic hemodialysis patients. Part 1: characterization and drug-related problems. Ann Pharmacother 1994;28:316-9.
6. Kaplan D, Shimp LA, Mason NA, Ascione FJ. Chronic hemodialysis patients. Part II: reducing drug-related problems through application of the focused drug therapy review program. Ann Pharmacother 1994;28:320-4.
7. Grabe DW, Low CL, Bailie GR, Eisele G. Evaluation of drug-related problems in an outpatient hemodialysis unit and the impact of a clinical pharmacist. Clin Nephrol 1997;47:117-21.
8. Cockroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
9. Blouin RA, Chandler MHH. Special pharmacokinetic considerations in the obese. In: Evans WE, Schentag JJ, Jusko WJ, eds. Applied pharmacokinetics: principles of therapeutic drug monitoring. 3rd ed. Vancouver, WA: Applied Therapeutics 1992:11.1-11.20.
10. Manley HJ, Carroll CA. The clinical and economic impact of pharmaceutical care in end-stage renal disease patients. Semin Dialysis 2002;15:45-9.
11. Strand LM, Morley PC, Cipolle RJ, Ramsey R, Lamsan GD. Drug-related problems: their structure and function. DICP 1990;24:1093-7.
12. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997;157:2413-46.
13. American Diabetes Association: clinical practice recommendations 2003. Diabetes Care 2003;26(suppl 1):S33-50.
14. Chertow GM, Lee J, Kuperman G, Gilad J, Burdick E, Horsky J, et al. Guided medication dosing for inpatients with renal insufficiency. JAMA 2001;286:2839-44.
15. Levey AS, Berg RL, Gassman JJ, Hall PM, Walker WG, and the Modification of Diet in Renal Disease (MDRD) Study Group. Creatinine filtration, secretion and excretion during progressive renal disease. Kidney Int 1989;36(suppl 27):S73-80.
16. McClellan WM, Knight DF, Karp H, Brown WW. Early detection and treatment of renal disease in hospitalized diabetic and hypertensive patients: important differences between practice and published guidelines (abstract). Am J Kidney Dis 1997;29:368-75.
17. Arora P, Obrador GT, Ruthazer R, Kausz AT, Meyer KB, Jenuleson CS, et al. Prevalence, predictors, and consequences of late nephropathy referral at a tertiary care center. J Am Soc Nephrol 1999;10:1281-6.
18. Kinchen KS, Sadler J, Fink N, Brookmeyer R, Klag MJ, Levey AS. The timing of specialist evaluation in chronic kidney disease and mortality. Ann Intern Med 2002;137:479-86.
19. Stack AG. Impact of timing of nephrology referral and pre-ESRD care on mortality risk among new ESRD patients in the US (letter). Am J Kidney Dis 2003;41:505-7.
20. Chisholm ME, Vollenweider LJ, Mulloy LL, Jagadeesan M, Wade WE, DiPirio JT, et al. Direct patient care services provided by a pharmacist on a multidisciplinary renal transplant team. Am J Health Syst Pharm 2000;57:1994-6.
21. Galt KA. Cost avoidance, acceptance, and outcomes associated with a pharmacotherapy consult clinic in a Veterans Affairs medical center. Pharmacotherapy 1998;181:103-11.